Bessemer Group
EIDX

Bessemer Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Bessemer Group’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-26,300
Closed -$1.25M – 1786
2020
Q2 		$1.25M Buy
+26,300
New +$1.22M ﹤0.01% 648

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Bessemer Group's EIDX Position: Q3 2020 in Review

Bessemer Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2020, closing a stake of 26,300 shares — an estimated $1.25M sold.

Bessemer Group first reported a position in EIDX in Q2 2020 and held it in 1 quarter. The position peaked at $1.25M in Q2 2020. 91 funds tracked by Wall St. Rank hold EIDX as of Q3 2020.

  • Bessemer Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
  • Bessemer Group sold 26,300 Eidos Therapeutics, Inc. Common Stock shares in Q3 2020, an estimated $1.25M.
  • Bessemer Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2020 and held it in 1 quarter.
  • Bessemer Group's Eidos Therapeutics, Inc. Common Stock position peaked at $1.25M in Q2 2020.
  • 91 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2020.

Based on Bessemer Group's 13F filing for Q3 2020, filed 12 Nov 2020.